Get access

Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs

Authors


  • This work was conducted in entirety at the Cummings School of Veterinary Medicine at Tufts University.

  • This study was not supported by any funding agency.

Address correspondence and reprint requests to
Dr. Therese E. O'Toole, Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, 200 Westboro Rd, North Grafton, MA 01356, USA. Email: theresa.otoole@tufts.edu

Abstract

Objective – To describe the use of IV and oral mycophenolate mofetil (MMF) as adjunctive therapy in 3 dogs with severe generalized myasthenia gravis.

Case Series Summary – Three dogs suffering from severe generalized myasthenia gravis as confirmed by acetylcholine antibody titers were treated with MMF as part of their treatment regimens. All 3 dogs had radiographic evidence of megaesophagus and suffered from severe regurgitation. Each dog was initially treated with pyridostigmine and supportive agents. When clinical remission was not achieved, IV MMF was administered to all dogs. Signs of clinical remission were apparent within 48 hours and all dogs were later maintained on oral MMF following resolution of regurgitation.

New or Unique Information Provided – This is the first report of the use of IV MMF as adjunctive treatment in dogs with severe generalized myasthenia gravis. Outcome was favorable in all 3 dogs and no adverse effects were noted from the MMF.

Get access to the full text of this article

Ancillary